Home » Newsletters » BioWorld

BioWorld

July 22, 2010

View Archived Issues

Euthymics Acquires DOV Pharma, Gets $24M Series A

PPAR-Gamma's Good and Bad Can 'Likely' Be Disconnected

Cara Banks $15M for Pursuit of Nonaddictive Pain Drug

FDA Restricts Enrollment in GSK's Avandia Study

Other News To Note

Stock Movers

Clinic Roundup

Appointments And Advancements

Economic Headwinds Knock Gilead, Genzyme Cuts Forecast

Earnings season got off to a rocky start for the biotech sector. (BioWorld Today) Read More

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...